Adlai Nortye Biopharma Co., Ltd. announced that it has received $100 million in its series D round of funding co-led by new investor SDIC Innovation Investment Management Co., Ltd. and existing investor Hangzhou Tigermed Consulting Co., Ltd. on July 13, 2021. The transaction also included participation from Beijing Legend Star Investment Management Co., Ltd.; WuXi AppTec Co., Ltd., Investment Arm; Shenzhen Qianhai Triwise International Capital Management Co., Ltd.; Wuxi Guolian Industry Investment Co., Ltd.; Qingdao Mukui Equity Investment Partnership Enterprise (L.P.), a fund managed by Hangtian Kegong Equity Investment Fund Management (Shenzhen) Co., Ltd.; Tian Ge Interactive Holdings Limited; Shanghai Ruihe Equity Investment Management Co., Ltd. and ATCG Holdings.